Designation of Ivacaftor (Kalydeco) as an Orphan drug - Vertex Pharmaceuticals (Australia) Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Commonwealth Parliament to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. One specific policy objective of the Act is to facilitate access to beneficial treatments for rare diseases by providing mechanisms to recognise and support the development of orphan drugs. On 24 November 2014, the Therapeutic Goods Administration designated Ivacaftor (KALYDECO) as an orphan drug for the treatment of cystic fibrosis in children aged 2 to 5 years with specific mutations in the CFTR gene, reflecting the Act's intent to address unmet medical needs in rare diseases.

Scope and Application

The Therapeutic Goods Act 1989, as amended and administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, encompasses the regulation of therapeutic goods to ensure their safety, quality, and efficacy. The designation of Ivacaftor (KALYDECO) as an orphan drug for the treatment of cystic fibrosis in patients aged 2 to 5 years with specific CFTR gene mutations is a specific application of this broader legislative framework. This designation applies to the sponsor of the drug, Vertex Pharmaceuticals (Australia) Pty Ltd, and the therapeutic good itself. The scope of the Act and its regulations is national, extending across all states and territories within Australia. There are no explicit exclusions or exemptions mentioned in the context of this designation, although the orphan drug criteria typically involve rare conditions with limited treatment options, thereby inherently excluding more common diseases or those with readily available treatments. The application and interpretation of the Act may be further detailed or extended through subordinate instruments, such as regulations and guidelines issued by the TGA.

Key Provisions

The primary operative sections of the Therapeutic Goods (Designation of Ivacaftor as an Orphan Drug) Determination 2014 include Section 16J of the Therapeutic Goods Regulations 1990. According to this, Dr. Anthony Gill, as the Delegate of the Secretary, has designated Ivacaftor (marketed as KALYDECO) as an orphan drug for a specific medical condition and age group. Specifically, Ivacaftor is designated for the treatment of cystic fibrosis (CF) in patients aged between 2 and 5 years old who have certain genetic mutations, namely gating (class III), R117H, Residual, or mRNA Splice Site (Class V) mutations in the CFTR gene (Section 16J(2)). The form of the drug designated is granules, and the sponsor of the drug is Vertex Pharmaceuticals (Australia) Pty Ltd. The designation of Ivacaftor as an orphan drug imposes certain obligations and requirements on the parties involved. Firstly, the sponsor, Vertex Pharmaceuticals (Australia) Pty Ltd, must ensure that Ivacaftor is manufactured and supplied in a manner that complies with the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This includes ensuring that the drug meets the required standards of quality, safety, and efficacy. Additionally, the sponsor must maintain records and documentation to demonstrate compliance with these legislative requirements. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in various legal consequences. Under the Therapeutic Goods Act 1989, breaches may be subject to civil or criminal penalties. The specific penalties can vary widely depending on the nature and severity of the breach, but they can include fines, imprisonment, or both. The Therapeutic Goods Regulations 1990 provide further detail on the potential penalties, which can include substantial fines for corporations and individuals. The exact penalties are not specified in the document but are detailed in the respective sections of the Act and Regulations. In summary, the Therapeutic Goods (Designation of Ivacaftor as an Orphan Drug) Determination 2014 designates Ivacaftor as an orphan drug for specific patients with cystic fibrosis, imposes compliance obligations on the sponsor, and outlines potential civil and criminal penalties for non-compliance. These provisions are designed to ensure that the drug is safe, effective, and available for the targeted patient group while maintaining high standards of pharmaceutical governance.